These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 30986804)

  • 1. Ethyl-2-amino-pyrrole-3-carboxylates are active against imatinib-resistant gastrointestinal stromal tumors in vitro and in vivo.
    Boichuk S; Galembikova A; Dunaev P; Micheeva E; Novikova M; Khromova N; Kopnin P
    Anticancer Drugs; 2019 Jun; 30(5):475-484. PubMed ID: 30986804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting of FGF-Signaling Re-Sensitizes Gastrointestinal Stromal Tumors (GIST) to Imatinib In Vitro and In Vivo.
    Boichuk S; Galembikova A; Dunaev P; Micheeva E; Valeeva E; Novikova M; Khromova N; Kopnin P
    Molecules; 2018 Oct; 23(10):. PubMed ID: 30326595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ethyl-2-amino-pyrrole-3-carboxylates are novel potent anticancer agents that affect tubulin polymerization, induce G2/M cell-cycle arrest, and effectively inhibit soft tissue cancer cell growth in vitro.
    Boichuk S; Galembikova A; Zykova S; Ramazanov B; Khusnutdinov R; Dunaev P; Khaibullina S; Lombardi V
    Anticancer Drugs; 2016 Aug; 27(7):620-34. PubMed ID: 27129079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Receptor Tyrosine Kinase Switch Promotes Gastrointestinal Stromal Tumor Drug Resistance.
    Boichuk S; Galembikova A; Dunaev P; Valeeva E; Shagimardanova E; Gusev O; Khaiboullina S
    Molecules; 2017 Dec; 22(12):. PubMed ID: 29206199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of fibroblast growth factor receptor-signaling sensitizes imatinib-resistant gastrointestinal stromal tumors to low doses of topoisomerase II inhibitors.
    Boichuk S; Dunaev P; Galembikova A; Mustafin I; Valeeva E
    Anticancer Drugs; 2018 Jul; 29(6):549-559. PubMed ID: 29697413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors.
    Chen W; Kuang Y; Qiu HB; Cao Z; Tu Y; Sheng Q; Eilers G; He Q; Li HL; Zhu M; Wang Y; Zhang R; Wu Y; Meng F; Fletcher JA; Ou WB
    Cancer Res; 2017 Sep; 77(18):5107-5117. PubMed ID: 28760855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KIT
    Banerjee S; Yoon H; Ting S; Tang CM; Yebra M; Wenzel AT; Yeerna H; Mesirov JP; Wechsler-Reya RJ; Tamayo P; Sicklick JK
    Mol Cancer Ther; 2021 Oct; 20(10):2035-2048. PubMed ID: 34376580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-30a targets BECLIN-1 to inactivate autophagy and sensitizes gastrointestinal stromal tumor cells to imatinib.
    Chen W; Li Z; Liu H; Jiang S; Wang G; Sun L; Li J; Wang X; Yu S; Huang J; Dong Y
    Cell Death Dis; 2020 Mar; 11(3):198. PubMed ID: 32251287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours.
    Saito Y; Takahashi T; Obata Y; Nishida T; Ohkubo S; Nakagawa F; Serada S; Fujimoto M; Ohkawara T; Nishigaki T; Sugase T; Koh M; Ishida T; Tanaka K; Miyazaki Y; Makino T; Kurokawa Y; Nakajima K; Yamasaki M; Hirota S; Naka T; Mori M; Doki Y
    Br J Cancer; 2020 Mar; 122(5):658-667. PubMed ID: 31857719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor.
    García-Valverde A; Rosell J; Serna G; Valverde C; Carles J; Nuciforo P; Fletcher JA; Arribas J; Politz O; Serrano C
    Mol Cancer Ther; 2020 Jun; 19(6):1289-1297. PubMed ID: 32371592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of FGFR2-Signaling Attenuates a Homology-Mediated DNA Repair in GIST and Sensitizes Them to DNA-Topoisomerase II Inhibitors.
    Sergei B; Pavel D; Aigul G; Firyuza B; Ilmira N; Ilshat M; Aida A; Refat K; Natalia A; Elena S; Vera G
    Int J Mol Sci; 2020 Jan; 21(1):. PubMed ID: 31948066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spectrum of activity of dasatinib against mutant KIT kinases associated with drug-sensitive and drug-resistant gastrointestinal stromal tumors.
    Zeng C; Zhu L; Jia X; Pang Y; Li Z; Lu X; Xie F; Duan L; Wang Y
    Gastric Cancer; 2020 Sep; 23(5):837-847. PubMed ID: 32291709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations.
    Floris G; Sciot R; Wozniak A; Van Looy T; Wellens J; Faa G; Normant E; Debiec-Rychter M; Schöffski P
    Clin Cancer Res; 2011 Sep; 17(17):5604-14. PubMed ID: 21737509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors.
    Cohen NA; Zeng S; Seifert AM; Kim TS; Sorenson EC; Greer JB; Beckman MJ; Santamaria-Barria JA; Crawley MH; Green BL; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
    Cancer Res; 2015 May; 75(10):2061-70. PubMed ID: 25836719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SPK1/S1P axis confers gastrointestinal stromal tumors (GISTs) resistance of imatinib.
    Chen Y; Zhang R; Mi D; Wang Q; Huang T; Dong X; Zhang H; Xiao H; Shi S
    Gastric Cancer; 2023 Jan; 26(1):26-43. PubMed ID: 35999321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RACK1 overexpression is linked to acquired imatinib resistance in gastrointestinal stromal tumor.
    Gao X; Xue A; Fang Y; Shu P; Ling J; Hou Y; Shen K; Qin J; Sun Y; Qin X
    Oncotarget; 2016 Mar; 7(12):14300-9. PubMed ID: 26893362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRD9 inhibition promotes PUMA-dependent apoptosis and augments the effect of imatinib in gastrointestinal stromal tumors.
    Mu J; Sun X; Zhao Z; Sun H; Sun P
    Cell Death Dis; 2021 Oct; 12(11):962. PubMed ID: 34667163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KIT over-expression by p55PIK-PI3K leads to Imatinib-resistance in patients with gastrointestinal stromal tumors.
    Lai S; Wang G; Cao X; Luo X; Wang G; Xia X; Hu J; Wang J
    Oncotarget; 2016 Jan; 7(2):1367-79. PubMed ID: 26587973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth.
    Serrano-Candelas E; Ainsua-Enrich E; Navinés-Ferrer A; Rodrigues P; García-Valverde A; Bazzocco S; Macaya I; Arribas J; Serrano C; Sayós J; Arango D; Martin M
    Mol Oncol; 2018 Aug; 12(8):1383-1397. PubMed ID: 29885053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unraveling the Mechanisms of Sensitivity to Anti-FGF Therapies in Imatinib-Resistant Gastrointestinal Stromal Tumors (GIST) Lacking Secondary
    Boichuk S; Dunaev P; Skripova V; Galembikova A; Bikinieva F; Shagimardanova E; Gazizova G; Deviatiiarov R; Valeeva E; Mikheeva E; Vasilyeva M; Kopnin P; Strelnikov V; Kiyamova R
    Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.